Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced the appointment of Jonathan M. Poole to the Board of Directors, effective March 3, 2026. Mr. Poole joins the Audit Committee and brings strong biopharmaceutical finance leadership supporting global innovation across therapeutic modalities. His experience strengthens financial oversight, strategic governance, and long-term corporate planning for Acadia’s growth strategies.
“Jonathan brings extensive biotechnology corporate leadership experience and a proven track record of supporting significant business growth across complex, global organizations,” said Stephen R. Biggar, M.D., Ph.D., Chairman of Acadia’s Board of Directors. “His appointment further strengthens the Board’s financial and operational expertise at a pivotal time as Acadia continues to execute its growth strategy, advance its commercial portfolio and pipeline, and deliver sustained, long‑term value for shareholders.”
“I am honored to join Acadia’s Board of Directors,” said Mr. Poole. “I look forward to working with the Board and management team to support the Company’s mission of developing and delivering innovative therapies for patients with significant unmet needs.”
Mr. Poole believes innovation drives sustainable healthcare transformation and shareholder confidence. Acadia continues advancing clinical research, commercialization strategy, and global market expansion initiatives.
Biopharmaceutical Finance Leadership and Academic Excellence
Mr. Poole has been serving as the Senior Vice President, Finance at Vertex Pharmaceuticals, Inc. since March 2020. In this capacity, he has been responsible for leading the global finance operations during the expansion of the R&D pipeline. In addition to this, he has been responsible for diversifying the commercial business, strategic acquisitions, and financial performance optimization. Previously, he served as the Chief Financial Officer at Evelo Biosciences, Inc. from March 2018 to March 2020. In this capacity, he supported the development of oral therapeutic candidates for the treatment of inflammation and cancer.
Earlier, from April 2014 to March 2018, Mr. Poole worked as Chief Financial Officer of Genocea Biosciences, Inc., supporting infectious disease and neoantigen cancer vaccine research and development programs. From July 2018 through March 2020, he also served as director of Codiak Biosciences, Inc., while chairing Audit Committee governance functions. Mr. Poole earned a B.Sc. Biological Sciences from Durham University and M.B.A. from London Business School, strengthening scientific and financial leadership capabilities.
For more stories on technology leaders shaping the future of enterprise solutions, visit our CXO Insiders.
Source: Businesswire
